The Experts below are selected from a list of 306 Experts worldwide ranked by ideXlab platform
Kwunyee T Poon - One of the best experts on this subject based on the ideXlab platform.
-
use of commercial anti penicillin ige fluorometric Enzyme Immunoassays to diagnose penicillin allergy
Annals of Allergy Asthma & Immunology, 2010Co-Authors: Eric Macy, Bruce J. Goldberg, Kwunyee T PoonAbstract:Background The intermittent unavailability of penicilloyl-polylysine since September 2000 has focused interest on commercial anti–penicillin IgE fluorometric Enzyme immunoassay (FEIA) tests to evaluate penicillin allergy. There has been no published comparison of commercial anti–penicillin IgE FEIAs and penicillin skin testing performed in the United States. Objective To determine whether the current commercial anti–penicillin IgE FEIAs can replace or augment penicillin skin testing and oral challenges when evaluating individuals with a history of penicillin allergy for future therapeutic penicillin tolerance. Methods A prospective convenience sample of 150 individuals with a history of penicillin allergy were evaluated between January 23, 2007, and August 4, 2009, with both penicillin skin tests and commercial anti–penicillin IgE FEIAs to penicillin G, penicillin V, and amoxicillin. All individuals with a negative penicillin skin test result underwent oral penicillin class antibiotic challenges. All individuals with a positive anti–penicillin IgE FEIA result also underwent oral penicillin class antibiotic challenges. Results Six individuals (4.0%; 95% confidence interval [CI], 0.9% to 7.1%) had positive penicillin skin test results, and none had positive FEIA results. Four individuals (2.7%; 95% CI, 0.1% to 5.3%) had positive FEIA results, and none had positive penicillin skin test results. Three individuals (2.0%; 95% CI, −0.2% to 4.2%) had positive oral challenge results, 1 with hives at 6 hours after challenge and 2 with delayed-onset (at >24 hours) nonurticarial rashes, and none had positive FEIA results. Conclusions The current commercial anti–penicillin IgE FEIAs are not useful in diagnosing penicillin allergy in patients with remote histories of penicillin allergy. Penicillin skin testing and, if the results are negative, an oral challenge remain the criterion standard tests to determine therapeutic penicillin tolerance.
-
use of commercial anti penicillin ige fluorometric Enzyme Immunoassays to diagnose penicillin allergy
Annals of Allergy Asthma & Immunology, 2010Co-Authors: Eric Macy, Bruce J. Goldberg, Kwunyee T PoonAbstract:Background The intermittent unavailability of penicilloyl-polylysine since September 2000 has focused interest on commercial anti–penicillin IgE fluorometric Enzyme immunoassay (FEIA) tests to evaluate penicillin allergy. There has been no published comparison of commercial anti–penicillin IgE FEIAs and penicillin skin testing performed in the United States. Objective To determine whether the current commercial anti–penicillin IgE FEIAs can replace or augment penicillin skin testing and oral challenges when evaluating individuals with a history of penicillin allergy for future therapeutic penicillin tolerance. Methods A prospective convenience sample of 150 individuals with a history of penicillin allergy were evaluated between January 23, 2007, and August 4, 2009, with both penicillin skin tests and commercial anti–penicillin IgE FEIAs to penicillin G, penicillin V, and amoxicillin. All individuals with a negative penicillin skin test result underwent oral penicillin class antibiotic challenges. All individuals with a positive anti–penicillin IgE FEIA result also underwent oral penicillin class antibiotic challenges. Results Six individuals (4.0%; 95% confidence interval [CI], 0.9% to 7.1%) had positive penicillin skin test results, and none had positive FEIA results. Four individuals (2.7%; 95% CI, 0.1% to 5.3%) had positive FEIA results, and none had positive penicillin skin test results. Three individuals (2.0%; 95% CI, −0.2% to 4.2%) had positive oral challenge results, 1 with hives at 6 hours after challenge and 2 with delayed-onset (at >24 hours) nonurticarial rashes, and none had positive FEIA results. Conclusions The current commercial anti–penicillin IgE FEIAs are not useful in diagnosing penicillin allergy in patients with remote histories of penicillin allergy. Penicillin skin testing and, if the results are negative, an oral challenge remain the criterion standard tests to determine therapeutic penicillin tolerance.
Eric Macy - One of the best experts on this subject based on the ideXlab platform.
-
use of commercial anti penicillin ige fluorometric Enzyme Immunoassays to diagnose penicillin allergy
Annals of Allergy Asthma & Immunology, 2010Co-Authors: Eric Macy, Bruce J. Goldberg, Kwunyee T PoonAbstract:Background The intermittent unavailability of penicilloyl-polylysine since September 2000 has focused interest on commercial anti–penicillin IgE fluorometric Enzyme immunoassay (FEIA) tests to evaluate penicillin allergy. There has been no published comparison of commercial anti–penicillin IgE FEIAs and penicillin skin testing performed in the United States. Objective To determine whether the current commercial anti–penicillin IgE FEIAs can replace or augment penicillin skin testing and oral challenges when evaluating individuals with a history of penicillin allergy for future therapeutic penicillin tolerance. Methods A prospective convenience sample of 150 individuals with a history of penicillin allergy were evaluated between January 23, 2007, and August 4, 2009, with both penicillin skin tests and commercial anti–penicillin IgE FEIAs to penicillin G, penicillin V, and amoxicillin. All individuals with a negative penicillin skin test result underwent oral penicillin class antibiotic challenges. All individuals with a positive anti–penicillin IgE FEIA result also underwent oral penicillin class antibiotic challenges. Results Six individuals (4.0%; 95% confidence interval [CI], 0.9% to 7.1%) had positive penicillin skin test results, and none had positive FEIA results. Four individuals (2.7%; 95% CI, 0.1% to 5.3%) had positive FEIA results, and none had positive penicillin skin test results. Three individuals (2.0%; 95% CI, −0.2% to 4.2%) had positive oral challenge results, 1 with hives at 6 hours after challenge and 2 with delayed-onset (at >24 hours) nonurticarial rashes, and none had positive FEIA results. Conclusions The current commercial anti–penicillin IgE FEIAs are not useful in diagnosing penicillin allergy in patients with remote histories of penicillin allergy. Penicillin skin testing and, if the results are negative, an oral challenge remain the criterion standard tests to determine therapeutic penicillin tolerance.
-
use of commercial anti penicillin ige fluorometric Enzyme Immunoassays to diagnose penicillin allergy
Annals of Allergy Asthma & Immunology, 2010Co-Authors: Eric Macy, Bruce J. Goldberg, Kwunyee T PoonAbstract:Background The intermittent unavailability of penicilloyl-polylysine since September 2000 has focused interest on commercial anti–penicillin IgE fluorometric Enzyme immunoassay (FEIA) tests to evaluate penicillin allergy. There has been no published comparison of commercial anti–penicillin IgE FEIAs and penicillin skin testing performed in the United States. Objective To determine whether the current commercial anti–penicillin IgE FEIAs can replace or augment penicillin skin testing and oral challenges when evaluating individuals with a history of penicillin allergy for future therapeutic penicillin tolerance. Methods A prospective convenience sample of 150 individuals with a history of penicillin allergy were evaluated between January 23, 2007, and August 4, 2009, with both penicillin skin tests and commercial anti–penicillin IgE FEIAs to penicillin G, penicillin V, and amoxicillin. All individuals with a negative penicillin skin test result underwent oral penicillin class antibiotic challenges. All individuals with a positive anti–penicillin IgE FEIA result also underwent oral penicillin class antibiotic challenges. Results Six individuals (4.0%; 95% confidence interval [CI], 0.9% to 7.1%) had positive penicillin skin test results, and none had positive FEIA results. Four individuals (2.7%; 95% CI, 0.1% to 5.3%) had positive FEIA results, and none had positive penicillin skin test results. Three individuals (2.0%; 95% CI, −0.2% to 4.2%) had positive oral challenge results, 1 with hives at 6 hours after challenge and 2 with delayed-onset (at >24 hours) nonurticarial rashes, and none had positive FEIA results. Conclusions The current commercial anti–penicillin IgE FEIAs are not useful in diagnosing penicillin allergy in patients with remote histories of penicillin allergy. Penicillin skin testing and, if the results are negative, an oral challenge remain the criterion standard tests to determine therapeutic penicillin tolerance.
Bruce J. Goldberg - One of the best experts on this subject based on the ideXlab platform.
-
use of commercial anti penicillin ige fluorometric Enzyme Immunoassays to diagnose penicillin allergy
Annals of Allergy Asthma & Immunology, 2010Co-Authors: Eric Macy, Bruce J. Goldberg, Kwunyee T PoonAbstract:Background The intermittent unavailability of penicilloyl-polylysine since September 2000 has focused interest on commercial anti–penicillin IgE fluorometric Enzyme immunoassay (FEIA) tests to evaluate penicillin allergy. There has been no published comparison of commercial anti–penicillin IgE FEIAs and penicillin skin testing performed in the United States. Objective To determine whether the current commercial anti–penicillin IgE FEIAs can replace or augment penicillin skin testing and oral challenges when evaluating individuals with a history of penicillin allergy for future therapeutic penicillin tolerance. Methods A prospective convenience sample of 150 individuals with a history of penicillin allergy were evaluated between January 23, 2007, and August 4, 2009, with both penicillin skin tests and commercial anti–penicillin IgE FEIAs to penicillin G, penicillin V, and amoxicillin. All individuals with a negative penicillin skin test result underwent oral penicillin class antibiotic challenges. All individuals with a positive anti–penicillin IgE FEIA result also underwent oral penicillin class antibiotic challenges. Results Six individuals (4.0%; 95% confidence interval [CI], 0.9% to 7.1%) had positive penicillin skin test results, and none had positive FEIA results. Four individuals (2.7%; 95% CI, 0.1% to 5.3%) had positive FEIA results, and none had positive penicillin skin test results. Three individuals (2.0%; 95% CI, −0.2% to 4.2%) had positive oral challenge results, 1 with hives at 6 hours after challenge and 2 with delayed-onset (at >24 hours) nonurticarial rashes, and none had positive FEIA results. Conclusions The current commercial anti–penicillin IgE FEIAs are not useful in diagnosing penicillin allergy in patients with remote histories of penicillin allergy. Penicillin skin testing and, if the results are negative, an oral challenge remain the criterion standard tests to determine therapeutic penicillin tolerance.
-
use of commercial anti penicillin ige fluorometric Enzyme Immunoassays to diagnose penicillin allergy
Annals of Allergy Asthma & Immunology, 2010Co-Authors: Eric Macy, Bruce J. Goldberg, Kwunyee T PoonAbstract:Background The intermittent unavailability of penicilloyl-polylysine since September 2000 has focused interest on commercial anti–penicillin IgE fluorometric Enzyme immunoassay (FEIA) tests to evaluate penicillin allergy. There has been no published comparison of commercial anti–penicillin IgE FEIAs and penicillin skin testing performed in the United States. Objective To determine whether the current commercial anti–penicillin IgE FEIAs can replace or augment penicillin skin testing and oral challenges when evaluating individuals with a history of penicillin allergy for future therapeutic penicillin tolerance. Methods A prospective convenience sample of 150 individuals with a history of penicillin allergy were evaluated between January 23, 2007, and August 4, 2009, with both penicillin skin tests and commercial anti–penicillin IgE FEIAs to penicillin G, penicillin V, and amoxicillin. All individuals with a negative penicillin skin test result underwent oral penicillin class antibiotic challenges. All individuals with a positive anti–penicillin IgE FEIA result also underwent oral penicillin class antibiotic challenges. Results Six individuals (4.0%; 95% confidence interval [CI], 0.9% to 7.1%) had positive penicillin skin test results, and none had positive FEIA results. Four individuals (2.7%; 95% CI, 0.1% to 5.3%) had positive FEIA results, and none had positive penicillin skin test results. Three individuals (2.0%; 95% CI, −0.2% to 4.2%) had positive oral challenge results, 1 with hives at 6 hours after challenge and 2 with delayed-onset (at >24 hours) nonurticarial rashes, and none had positive FEIA results. Conclusions The current commercial anti–penicillin IgE FEIAs are not useful in diagnosing penicillin allergy in patients with remote histories of penicillin allergy. Penicillin skin testing and, if the results are negative, an oral challenge remain the criterion standard tests to determine therapeutic penicillin tolerance.
Rhoda Ashley - One of the best experts on this subject based on the ideXlab platform.
-
longitudinal reliability of focus glycoprotein g based type specific Enzyme Immunoassays for detection of herpes simplex virus types 1 and 2 in women
Journal of Clinical Microbiology, 2003Co-Authors: Thomas L Cherpes, Rhoda Ashley, Leslie A Meyn, Sharon L HillierAbstract:Serologic assays that utilize herpes simplex virus (HSV) type-specific glycoproteins G-1 (HSV-1) and G-2 (HSV-2) to discriminate between antibodies against HSV-1 and HSV-2 are sensitive and specific. However, the high rates of seroreversion, defined as the change in an individual's antibody status from positive to negative over time, previously reported in longitudinal evaluations of glycoprotein G type-specific tests suggests that their use in HSV acquisitional studies would be problematic. To further explore the reliability of the glycoprotein G-based serologic tests, we evaluated HSV-1 and HSV-2 Enzyme Immunoassays from Focus Technologies in a longitudinal cohort of 1,207 young women from Pittsburgh, Pa. On enrollment of the women in the study, HSV-1 and HSV-2 antibodies were detected in 46.6 and 24.9% of the women, respectively. Among the women with at least three visits, 3.4% (15 of 447) of those who were HSV-1 antibody positive had a subsequent negative result while fewer than 1% (2 of 227) of those who were HSV-2 antibody positive seroreverted. The median of mean positive index values for women who seroreverted to HSV-1 antibody was lower than that for women who remained seropositive (1.25 versus 7.06; P < 0.001). Similarly, the median of mean positive index values for women whose HSV-2 antibody status reverted from positive to negative was lower than that for those women who did not serorevert (1.83 versus 7.46; P = 0.02). Comparative Western blot analysis demonstrated that the lower positive index values, seen more often among the HSV seroreverters, often signified false-positive immunoassay results. Overall, the seroreversion rates were low; the use of glycoprotein G-based serologic tests for the measurement of HSV-1 and HSV-2 antibodies in incidence studies therefore appears warranted.
-
inability of Enzyme Immunoassays to discriminate between infections with herpes simplex virus types 1 and 2
Annals of Internal Medicine, 1991Co-Authors: Rhoda Ashley, Anne Cent, Vanna Maggs, Andre J Nahmias, Lawrence CoreyAbstract:Abstract ▪Objective:To determine the accuracy of three commercial Enzyme Immunoassays in detecting and subtyping antibodies to herpes simplex virus type 1 or 2. ▪Design:Cross-sectional. ▪Setting:Re...
Lawrence Corey - One of the best experts on this subject based on the ideXlab platform.
-
inability of Enzyme Immunoassays to discriminate between infections with herpes simplex virus types 1 and 2
Annals of Internal Medicine, 1991Co-Authors: Rhoda Ashley, Anne Cent, Vanna Maggs, Andre J Nahmias, Lawrence CoreyAbstract:Abstract ▪Objective:To determine the accuracy of three commercial Enzyme Immunoassays in detecting and subtyping antibodies to herpes simplex virus type 1 or 2. ▪Design:Cross-sectional. ▪Setting:Re...